Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL CYPIONATE versus STILPHOSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL CYPIONATE versus STILPHOSTROL.
ESTRADIOL CYPIONATE vs STILPHOSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol cypionate is a synthetic ester of estradiol, a form of estrogen. It binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and leading to effects such as development of female secondary sexual characteristics, regulation of menstrual cycle, and maintenance of reproductive tissues. It also has effects on bone density, lipid metabolism, and coagulation factors.
Synthetic nonsteroidal estrogen; binds to estrogen receptors, inducing tumor regression in hormone-sensitive cancers.
1-5 mg intramuscularly every 3-4 weeks.
0.5-1 mg/kg intravenously daily for 5 days, then 0.5 mg/kg intramuscularly weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 7–9 days following intramuscular injection, reflecting prolonged absorption from the oil depot.
Terminal elimination half-life: 50-60 hours (range 40-80 hr) due to enterohepatic recirculation; clinical context: steady-state achieved in ~10-14 days
Primarily renal (approximately 90% as glucuronide and sulfate conjugates; less than 5% as unchanged drug). Biliary/fecal elimination accounts for about 10%.
Renal (primarily as glucuronide conjugates, 70-80%); fecal (biliary excretion of conjugates, 20-30%); <5% unchanged
Category D/X
Category C
Estrogen
Estrogen